Month: September 2026

Advanced multi-omics data analysis and biostatistical expertise to sharpen target and biomarker decisions across the platform

PRINCETON, N.J., and NEW HAVEN, Conn., Sept. 14, 2026 (GLOBE NEWSWIRE) — Niki BioSolutions, Inc. (NASDAQ: NIKI) (“Niki” or the “Company”), a clinical-stage life sciences company focused on unmet medical needs and genomic and biomarker testing solutions, today announced that its wholly owned subsidiary, DiamiR Biosciences Corp. (“DiamiR”), has engaged Fios Genomics, a specialist provider of bioinformatics and biostatistics services, to perform bioinformatics and statistical analysis in support of the Company’s Alzheimer’s disease program. Under the engagement, Fios Genomics will analyze and interpret data generated across the program to help Niki BioSolutions advance its Alzheimer’s assays through the development pipeline.

Alzheimer’s disease affects tens of millions of people worldwide and remains one of the most significant unmet needs in medicine. Robust, reproducible analysis of complex biological datasets is essential to identifying meaningful biological signals, validating targets and biomarkers, and making well-informed decisions at each stage of development. Fios Genomics brings deep experience in the analysis of genomic, transcriptomic, proteomic, and other large, complex biological datasets, together with rigorous statistical methodology, to help translate raw data into actionable insight.

“Engaging Fios Genomics is an important step forward for our Alzheimer’s program,” said Alidad Mireskandari, Ph.D., President and Chief Operating Officer of Niki BioSolutions. “The datasets generated in this project are large and complex, and getting the analysis right is critical to the decisions we make next. Fios Genomics has a strong track record of delivering high-quality, independent bioinformatics and statistical analysis for life sciences organizations, and its expertise allows our team to stay focused on advancing the science. We look forward to a productive collaboration as we work to bring new options to people at risk of or living with Alzheimer’s disease.”

As part of the engagement, Fios Genomics will provide end-to-end analytical support, including data quality assessment, statistical analysis and interpretation of current datasets, and the delivery of clear, decision-ready reports to Niki BioSolutions’ research and development team. The work is expected to inform target and biomarker prioritization and support the design of subsequent validation studies within the pipeline.

About Niki BioSolutions

Niki BioSolutions is a clinical-stage life sciences company focused on unmet medical needs and on providing high-quality genomic and biomarker testing solutions to healthcare providers, research institutions, and life sciences organizations through its CLIA-certified, CAP-accredited laboratory. The company combines proprietary technologies with a commitment to scientific rigor to support precision medicine across a range of therapeutic areas, including brain health and oncology. Niki BioSolutions collaborates with leading academic centers, disease foundations, and biopharma companies.

About Fios Genomics

Fios Genomics is a specialist provider of bioinformatics and biostatistics services to the pharmaceutical, biotechnology, and academic sectors. The company supports research and development programs with data analysis and interpretation across genomics, transcriptomics, proteomics, and other high-throughput data types, from early discovery through clinical development. Fios Genomics is headquartered in Edinburgh, United Kingdom. For more information, visit www.fiosgenomics.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements often use words such as “believe,” “may,” “will,” “estimate,” “target,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “propose,” “plan,” “project,” “forecast,” “predict,” “potential,” “seek,” “future,” “outlook,” and similar variations and expressions. Forward-looking statements are those that do not relate strictly to historical or current facts. Examples of forward-looking statements may include, among others, Niki BioSolutions’ ability to successfully operate its business and provide value to stockholders; Niki BioSolutions’ future financial, business and operating performance and goals; annualized recurring revenue and customer retention; ongoing or future ability to maintain or improve its financial position, cash flows, and liquidity and its expected financial needs; potential financing and ability to obtain financing; acquisition strategy and proposed acquisitions and, if completed, their potential success and financial contributions; strategy and strategic goals, including being able to capitalize on opportunities; expectations relating to Niki BioSolutions and its industry, outlook and market trends; total addressable market and serviceable addressable market and related projections; plans, strategies and expectations for increasing revenue and executing growth initiatives. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity and development of the industries in which Niki BioSolutions operates may differ materially from those made in or suggested by the forward-looking statements. Therefore, investors should not rely on any of these forward-looking statements. Factors that may cause actual results to differ materially include changes in the markets in which Niki BioSolutions operates, the financial markets, economic, business and regulatory factors, and other factors, such as Niki BioSolutions’ ability to execute on its strategies. More detailed information about risk factors can be found in the registration statement on Form S-4 filed with the Securities and Exchange Commission (the “SEC”) on October 6, 2025 (File No. 333-290742), and in other reports filed under the company’s prior name, Aptorum Group Limited, and that will be filed by Niki BioSolutions with the SEC. Niki BioSolutions does not undertake any duty to update forward-looking statements after the date of this press release.

Investor Contact:

Lytham Partners, LLC
Ben Shamsian
646-829-9701
shamsian@lythampartners.com

The joint project is designed to validate next-generation power architecture for GPU systems, an important precursor to large-scale manufacturing and industry certification

SAN FRANCISCO, Sept. 14, 2026 (GLOBE NEWSWIRE) — Exascale Labs Holdings Inc. (“Exascale”) (Nasdaq: XLAB), a next-generation AI infrastructure provider, today announced that it has entered into a non-binding Letter of Intent with Compal Electronics, Inc. (“Compal”) (TWSE: 2324), a global IT solutions leader, to jointly develop a U.S.-based platform for next-generation GPU systems. The platform will be built on a native 800-volt direct current (VDC) architecture using solid-state transformer (SST) technology to test how GPU computing systems perform in a fully integrated AI data center environment.

The platform will combine Compal’s production-grade GPU server platforms and liquid cooling systems with Exascale’s Modular Data Center (MDC) and SST power architecture to validate power, compute, cooling, and controls as an integrated system. As GPU rack densities increase, the industry is exploring 800 VDC to reduce conversion stages and improve power distribution efficiency. At present, integrated physical validation across power, servers, cooling, and software controls remains limited. The project is designed to bring both companies’ production-grade hardware into a shared testing environment, allowing electrical, thermal, mechanical and software interfaces to be engineered and validated together before deployment.

A production-grade validation platform for next-generation GPU infrastructure

Under the anticipated division of responsibilities, Compal will provide the U.S. project site, GPU servers, and liquid cooling systems. Exascale will design the modular data center system, SST-based power architecture and related software systems, and will lead the end-to-end deployment, commissioning, and testing of the platform.

“The goal is to validate native 800 VDC across a complete data center system,” said Dr. Hoansoo Lee, Chief Executive Officer of Exascale. “Compal’s planned contribution of the site, GPU servers and cooling systems will allow us to test our SST power architecture and modular infrastructure alongside the equipment they are intended to support. That integration is an important step toward commercial deployment.”

Expected platform capabilities

• Validating SST operational availability in a data-center-grade, end-to-end environment, while accumulating the experience and data needed to support volume production and the UL certification process;
• Conducting native 800 VDC compatibility testing and pre-shipment power-on testing for GPU servers;
• Providing a test and validation environment for upstream and downstream ecosystem partners; and
• Accumulating experience and data toward the development of standardized, data-center-grade native 800 VDC solutions and the attainment of industry certifications.

From joint development to product acquisition

Following completion of the platform and successful acceptance testing agreed by the parties, Compal intends, subject to the definitive agreement, to acquire the portion of the platform developed and provided by Exascale, including the SST systems, power distribution equipment, modular data center facilities and software use licenses. The definitive agreement would establish the final acquisition scope, purchase price, closing conditions and other commercial terms.

“Power, compute, and cooling all have to work as one system. Native 800 VDC is not simply a new power input for the server— it requires the server, power system, cooling, and controls to operate as an integrated system,” said Alan Chang, VP and GM of ISBG of Compal. “By integrating our GPU servers and cooling systems into the development process from the outset, we can validate the complete infrastructure under real operating conditions and build a repeatable architecture that can support future high-density AI deployments at scale.”

About Exascale

Exascale is a next-generation AI infrastructure provider operating a software-defined GPU compute platform and related AI infrastructure solutions. Its business includes Token Factory, GPU-as-a-service, GPU cluster management and optimization, and infrastructure solutions spanning modular data centers, HVDC power, high-density cooling, and data center interconnectivity. Exascale’s platform supports large-scale AI workloads, including training, fine-tuning, high-concurrency inference, and API-based token generation. For more information, visit www.exascalelabs.ai.

About Compal

Founded in 1984, Compal is a leading global manufacturer of computers and smart devices and a Forbes Global 2000 company, partnering with top-tier brands worldwide. Compal has expanded into cloud servers, automotive electronics, smart medical and healthcare, and advanced communication solutions. Headquartered in Taipei, Taiwan, Compal operates globally across the United States, Taiwan, China, Vietnam, Mexico, Brazil, and Poland. Learn more at https://www.compal.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as “anticipate,” “believe,” “can,” “continue,” “could,” “expect,” “intend,” “may,” “plan,” “project,” “seek,” “should,” “will,” and similar expressions. These statements include, without limitation, statements regarding the anticipated development, deployment, commissioning, testing and capabilities of the proposed platform, the potential validation of a native 800 VDC architecture, the anticipated contributions and responsibilities of the parties, the potential benefits, performance, efficiency, scalability and commercial applications of the proposed platform and related technologies, and Compal’s intention to acquire certain portions of the platform developed and provided by Exascale. These statements are based on current expectations and assumptions, and involve risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements, including, among others, the ability of the parties to successfully develop and integrate the proposed platform, the ability to achieve anticipated power, thermal, mechanical or software integration objectives, the ability to commercialize the resulting technology, competition in AI infrastructure and data-center markets, financing and capital requirements, and other risks and uncertainties described from time to time in Exascale’s filings with the Securities and Exchange Commission. In addition, the Letter of Intent is non-binding, and there can be no assurance that the parties will enter into a definitive agreement, that the proposed platform will be completed or accepted, or that Compal will ultimately acquire any portion of the platform.

If any of these risks materialize or the assumptions prove incorrect, actual results could differ materially from the results contained in or implied by these forward-looking statements. There may be additional risks that Exascale does not presently know or cannot currently anticipate or that Exascale currently believes are immaterial that could also cause actual results to differ materially from those contained in or implied by the forward-looking statements.

The forward-looking statements speak only as of the date of this press release. Exascale undertakes no obligation to update or revise any forward-looking statements, except as required by law.

Investor Contact

Nick Hresko-Staab
KCSA Strategic Communications
Exascale@KCSA.com

Media Contact

Hannah Erger
KCSA Strategic Communications
Exascale@KCSA.com

Initial Advance of $2.5 Million to Realbotix LLC to Support Growth and Working Capital; Non-Interest Bearing Facility Is Automatically Cancelled and Discharged in Full Upon Closing of Pending Acquisition

CINCINNATI, Ohio, Sept. 14, 2026 (GLOBE NEWSWIRE) — Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) today announced that it has provided a strategic bridge financing facility of up to $5,000,000 to Realbotix LLC (“Realbotix”), the target of its previously announced pending acquisition, to support Realbotix’s growth and working capital needs while the parties advance toward closing of the acquisition. The financing was provided in connection with the Share Exchange Agreement between the two companies, announced on February 12, 2026.

The facility provides for an aggregate principal amount of up to $5,000,000, with an initial advance of $2,500,000.

The facility is non-interest bearing prior to the closing of the Share Exchange Agreement. Upon closing of the acquisition, the facility and all obligations thereunder will be automatically cancelled and discharged in full. In addition, the cash required at closing of the acquisitions will be reduced by the total principal advanced under the facility plus an additional $500,000. If the Share Exchange Agreement is terminated, interest accrues at 12% per annum from the date of termination. A description of the Note is included in Onconetix’s Current Report on Form 8-K filed with the SEC on [DATE], 2026. The full text of the Note is filed as an exhibit to that report and is available at www.sec.gov.

As previously announced on February 12, 2026, Onconetix entered into the Share Exchange Agreement to acquire 100% of the issued and outstanding equity interests of Realbotix LLC in an all-stock transaction. The combined company is expected to trade on Nasdaq following closing, which is subject to Onconetix shareholder approval, required regulatory approvals, and other closing conditions.

This communication is being provided for informational purposes only. Investors are cautioned not to place undue reliance on forward-looking or projected information.

About Onconetix, Inc.

Onconetix, Inc. (Nasdaq: ONCO) is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative oncology solutions. Onconetix owns Proclarix®, an in vitro diagnostic test for prostate cancer originally developed by Proteomedix and approved for sale in the European Union under the IVDR, which it anticipates will be marketed in the U.S. as a lab developed test through its license agreement with Labcorp. For more information, visit www.onconetix.com.

About Realbotix LLC

Realbotix LLC is a wholly-owned subsidiary of Realbotix Corp. (TSX-V: XBOT; Frankfurt: 76M0.F; OTC: XBOTF) and the target of Onconetix’s pending acquisition. Realbotix LLC develops AI-powered humanoid robots designed for human interaction across enterprise and consumer environments. Manufactured in the United States, Realbotix’s patented AI and robotics technologies enable lifelike expressions, motion, vision, and social engagement. For more information, visit www.realbotix.ai.

Additional Information and Where to Find It

In connection with the proposed transaction between Realbotix and Onconetix, Onconetix intends to file with the SEC a Registration Statement on Form S-4 (the “Registration Statement”) to register the common stock to be issued by Onconetix in connection with the proposed transaction. The Registration Statement will include a proxy statement of Onconetix and a prospectus of Onconetix (the “Proxy Statement/Prospectus”), and each of Realbotix and Onconetix may file with the SEC other relevant documents concerning the proposed transaction. After the Registration Statement is declared effective, the definitive Proxy Statement/Prospectus will be sent to the stockholders of Onconetix to seek their approval of the proposed transaction. This is not a substitute for the Registration Statement, the Proxy Statement/Prospectus or any other relevant documents that Realbotix or Onconetix has filed or will file with the SEC. BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, INVESTORS AND STOCKHOLDERS OF ONCONETIX ARE URGED TO CAREFULLY AND ENTIRELY READ THE REGISTRATION STATEMENT AND PROXY STATEMENT/PROSPECTUS REGARDING THE PROPOSED TRANSACTION AND ANY OTHER RELEVANT DOCUMENTS, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS, IF AND WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT REALBOTIX, ONCONETIX, THE PROPOSED TRANSACTION, AND RELATED MATTERS.

A copy of the Registration Statement, Proxy Statement/Prospectus, as well as other relevant documents filed by Realbotix and Onconetix with the SEC, may be obtained free of charge, when they become available, at the SEC’s website at www.sec.gov. The information on Realbotix or Onconetix’s respective websites is not, and shall not be deemed to be, a part of this communication or incorporated into other filings either company makes with the SEC.

Participants in the Solicitation

Realbotix, Onconetix and certain of their respective directors, executive officers, and employees may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction. Information about the directors and executive officers of Onconetix, their ownership of Onconetix common stock, and Onconetix’s transactions with related persons is set forth in the 10-K, as filed with the SEC on March 13, 2026, and other documents that may be filed from time to time with the SEC. Additional information about the directors and executive officers of Realbotix and Onconetix and other persons who may be deemed to be participants in the solicitation of stockholders of Onconetix in connection with the proposed transaction and a description of their direct and indirect interests will be included in the Proxy Statement/Prospectus related to the proposed transaction or other relevant materials, which will be filed with the SEC. These documents may be obtained free of charge, when they become available, at the SEC’s website at www.sec.gov and from Onconetix using the sources indicated above.

No Offer or Solicitation

This communication is for informational purposes only and is not intended to and does not constitute an offer to sell or the solicitation of an offer to buy or sell any securities or the solicitation of any proxy, vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act, or in a transaction exempt from the registration requirements of the Securities Act.

Forward-Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements (including, without limitation, the anticipated benefits and opportunities that may be generated by the proposed transaction described herein) are based on Onconetix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, the occurrence of any event, change, or other circumstances that could give rise to the right of one or both of the parties to terminate the share exchange agreement; the possibility that the proposed transaction does not close when expected or at all because the conditions to closing are not satisfied on a timely basis or at all, including the failure to timely obtain stockholder approval for the proposed transaction from Onconetix’s stockholders, if at all; risks related to Onconetix’s continued listing on Nasdaq until closing of the proposed transaction; the outcome of any legal proceedings that may be instituted against Realbotix, Onconetix, or the combined company; the possibility that the anticipated benefits of the proposed transaction are not realized when expected or at all; the possibility that the vision, goals, and trajectory of the combined company are not timely achieved or realized or achieved or realized at all; the possibility that the proposed transaction may be more expensive or take longer to complete than anticipated, including as a result of unexpected factors or events; the diversion of management’s attention from ongoing business operations and opportunities; changes in Onconetix’s stock price before closing; and other factors that may affect future results of Realbotix, Onconetix, or the combined company. Onconetix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Onconetix’s Annual Report on Form 10-K filed with the SEC on March 13, 2026 (the “10-K”) and periodic reports filed with the SEC on or after the date thereof. All of Onconetix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Investor and Media Contact:
Onconetix, Inc.
201 E. Fifth Street, Suite 1900
Cincinnati, OH 45202
Phone: (513) 620-4101
Email: investors@onconetix.com

PEKIN, Ill., Sept. 14, 2026 (GLOBE NEWSWIRE) — Alto Ingredients, Inc. (NASDAQ: ALTO), a producer and distributor of renewable fuel, essential ingredients and specialty alcohols, today announced that management will take part in the H.C. Wainwright 28th Annual Global Investment Conference, conducting one-on-one meetings throughout the day on Tuesday, September 15, 2026.

About Alto Ingredients, Inc.
Alto Ingredients, Inc. (NASDAQ: ALTO) is a leading producer and distributor of renewable fuels, essential ingredients and specialty alcohols. Leveraging the unique qualities of its facilities, the company serves customers in a wide range of consumer and commercial products in the Health, Home & Beauty; Food & Beverage; Industry & Agriculture; Essential Ingredients; and Renewable Fuels markets. For more information, please visit www.altoingredients.com.

Media and Company IR Contact:
Michael Kramer, Alto Ingredients, Inc., 916-403-2755
Investorrelations@altoingredients.com 

IR Agency Contact:
Jody Burfening, Alliance Advisors Investor Relations, 212-838-3777
Investorrelations@altoingredients.com

First advance under second tranche brings total drawn under the DOE facility to $178 million and supports 4 GWh of annual battery manufacturing capacity in Western Pennsylvania

PITTSBURGH, Sept. 14, 2026 (GLOBE NEWSWIRE) — Eos Energy Enterprises, Inc. (NASDAQ: EOSE) (“Eos” or the “Company”), America’s leading innovator in designing, manufacturing, and providing zinc-based long-duration energy storage (LDES) systems sourced and manufactured in the United States, today announced it has received an $87 million first advance under the second tranche of its loan agreement with the U.S. Department of Energy’s (DOE) Office of Energy Dominance Financing (EDF).

The advance reimburses 80% of eligible costs associated with the Company’s Thorn Hill manufacturing facility in Warrendale, Pennsylvania. Eos has now drawn a total of approximately $178 million of its DOE facility since 2024.

Line 2 entered commercial production in June 2026 and is being ramped toward its designed annual manufacturing capacity of approximately 2 GWh. Upon completion of the planned relocation of line 1 to Thorn Hill, subject to lender approvals, Eos expects Thorn Hill to support approximately 4 GWh of annual manufacturing capacity across two lines.

“Loan funding from the Office of Energy Dominance Financing has been critical in scaling Eos,” said Alessandro Lagi, Chief Financial Officer of Eos. “This advance reimburses a significant portion of the investment we have already made in Line 2 and returns that capital to the balance sheet, giving us more room to invest in the business while maintaining a disciplined approach to growth.”

“Running two lines under one roof drives more efficient use of our engineering, support resources, and labor,” said John Mahaz, Chief Operating Officer of Eos. “This enables the operation to increase productivity and optimize manufacturing cost.”

Eos expects to create jobs across 4 shifts to staff Line 2 in the Western Pennsylvania facility. The line continues to ramp toward full production as additional shifts come online, consistent with the Company’s phased manufacturing scale-up strategy.

About Eos Energy Enterprises

Eos is accelerating the shift to American energy independence with positively ingenious solutions that transform how the world stores power. The Company’s BESS features the innovative Znyth™ technology, a proven chemistry with readily available non-precious earth components, that is the pre-eminent safe, non-flammable, secure, stable, and scalable alternative to conventional technology. The Company’s BESS is ideal for utility-scale, microgrid, commercial, and industrial long-duration energy storage applications (i.e., 4 to 16+ hours), and provides customers with significant operational flexibility to effectively address current and future increased grid demand and complexity. For more information about Eos (NASDAQ: EOSE), visit eose.com.

Contacts

Investors: ir@eose.com
Media: media@eose.com

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the expected use and benefits of the loan proceeds; the continued development, installation, startup, operation, and ramp-up of Line 2; the expansion and scaling of Eos’ manufacturing operations and domestic manufacturing capacity; the timing and achievement of targeted production levels and annual manufacturing capacity; the anticipated staffing, hiring, and job creation associated with Line 2; the availability of future advances under the DOE-guaranteed loan facility; the receipt of any required lender or governmental approvals; and Eos’ ability to execute its growth strategy, and other statements that are not historical facts. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are based on our management’s current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.

Important factors that could cause actual results to differ materially include, among others, risks relating to Eos’ ability to satisfy the conditions applicable to future advances under the DOE-guaranteed loan facility; complete, commission, operate, and ramp Line 2 on the anticipated schedule and within the applicable budget; achieve targeted production rates, staffing levels, hiring objectives, and manufacturing capacity; manage construction, equipment, supply-chain, labor, startup, and operational risks; obtain and maintain required governmental and third-party approvals; comply with the DOE loan documents and other financing arrangements; maintain adequate liquidity and secure additional financing when needed; realize anticipated manufacturing efficiencies, productivity improvements, cost benefits, and operational synergies associated with consolidating manufacturing activities; and scale manufacturing operations, and other risks described in Eos’ filings with the Securities and Exchange Commission (“SEC”).

Additional information concerning these and other risk factors is contained in the Company’s filings with the SEC, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.

Forward-looking statements speak only as of the date they are made. Should one or more of these risks or uncertainties materialize or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Readers are cautioned not to put undue reliance on forward-looking statements, and, except as required by law, the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

Initial members bring global rare earths leadership, direct Skaergaard technical knowledge, and proven mine-development and operating experience in Greenland

Advisory Board to support project strategy, studies, permitting, partnerships and the Company’s North Atlantic Critical Metals Corridor

CHARLOTTE, N.C., Sept. 14, 2026 (GLOBE NEWSWIRE) — via IBN – Greenland Mines Ltd. (Nasdaq: GRML) (“Greenland Mines” or the “Company”) today announced the formation of a Strategic Advisory Board and the appointment of its three initial members: Constantine E. Karayannopoulos, Thomas Abraham-James, and Bent Olsvig Jensen.

The Strategic Advisory Board brings together complementary capabilities across the full development pathway for Greenland Mines’ two flagship assets: global rare earth markets, processing and downstream supply chains; direct technical and operating history at the Skaergaard Palladium-Platinum-Gold project; and practical mine development, operations, logistics and stakeholder engagement in Greenland including managing and operation experience from the nearby anorthosite mine only 40 km away from Greenland Mines’ Sarfartoq Neodymium-Praseodymium Rare Earth Project.

Greenland Mines intends to appoint two to three additional members as it continues to broaden the expertise and relationships available to management and the Company’s Board of Directors.

“The creation of our Strategic Advisory Board reflects where Greenland Mines is today and where we intend to go next,” said Dr. Bo Møller Stensgaard, President of Greenland Mines.

“Over the past several months, we have completed the acquisition of Sarfartoq, delivered new S-K 1300 Mineral Resource Estimates for both projects and executed the most extensive multidisciplinary field program undertaken at Skaergaard to date.

“We are now advancing from resource definition and data collection into the next stage of technical studies, permitting, commercial engagement and integrated development planning.

“Constantine, Tom and Bent bring an exceptional combination of capabilities for this next phase for the Company and its Sarfartoq Rare Earth Project and Skaergaard Precious and Critical Metals Project.

“Constantine is a transformational addition to Greenland Mines. Over more than three decades, he has built, led and completed major transactions across the international rare earth and critical-materials industries, with experience spanning mineral resources, separation, advanced materials and permanent-magnet supply chains. He combines deep technical and commercial expertise with an exceptional international network across industry, capital markets and governments in North America, Europe and Asia.

“Constantine also brings a direct and highly relevant connection to Sarfartoq. As President and Chief Executive Officer of Neo Performance Materials, he was instrumental in Neo’s decision to acquire and advance Sarfartoq as a potential source of NdPr-rich feedstock for a more diversified Western rare earth supply chain. His ability to connect high-quality mineral resources with processing capacity, strategic partners, government priorities and end markets will be invaluable as we advance Sarfartoq and develop our broader North Atlantic Critical Metals Corridor. He will be an important strategic sounding board for our leadership and a powerful facilitator of the relationships required to move our vision forward.

“Tom brings first-hand knowledge of Skaergaard and a strong record spanning exploration, public markets and company building. Through his leadership of Pulsar Helium, he has also demonstrated an ability to position critical-resource projects within broader strategic supply-chain priorities — combining upstream resource development with processing infrastructure, financing, constructive government engagement and local stakeholder support.

“Bent brings proven Greenland mine-operating experience from the nearby producing Greenlandic anorthosite in West Greenland — only 40 km west of Sarfartoq — and an important understanding of how projects must be planned and executed in close cooperation with Greenlandic authorities, communities, businesses and the local workforce.

“The Advisory Board will be a practical sounding board for strategy, development sequencing and execution. It will also support our work to connect Greenlandic mineral resources with allied processing capabilities, capital, government initiatives and end markets. That is central to our North Atlantic Critical Metals Corridor: not simply moving material from one location to another, but building resilient, responsible and commercially viable links across the upstream, midstream and downstream value chain.”

Initial Advisory Board Members

Constantine E. Karayannopoulos

Mr. Karayannopoulos, BASc, MASc, P.Eng., is an experienced executive and professional engineer with more than 30 years of senior leadership roles in the rare earth elements, critical minerals, and advanced materials sectors. He has held senior executive and board roles across mining, processing and downstream materials businesses globally.

He most recently served as President and Chief Executive Officer of Neo Performance Materials Inc. (NEO) until his retirement in July 2023. During his tenure with NEO and its predecessors from 2000, he held several senior leadership roles including COO, CEO, Chairman, and again CEO from 2020 to 2023.

As CEO of Neo, he oversaw the company’s global expansion and ultimately led the company through its US$1.3 billion acquisition by Molycorp Inc. in 2012. Following the transaction, he served as Vice-Chairman, later becoming interim Chief Executive Officer and Chairman of Molycorp.

Mr. Karayannopoulos is also the co-founder and former non-executive Chairman of Neo Lithium Corp., which developed a major lithium brine project in Argentina before being acquired in 2022 for approximately US$960 million. In addition to his corporate roles, Mr. Karayannopoulos serves as a strategic advisor and board member to several companies in the critical minerals and battery materials sectors.

He has previously served as a director of the Canada China Business Council and sits on the advisory board of the University of Toronto Department of Chemical Engineering and Applied Chemistry. He holds Bachelor and Master of Applied Science degrees in Chemical Engineering from the University of Toronto and is a registered Professional Engineer.

Mr. Karayannopoulos also has direct historical involvement with Sarfartoq. While he was President and Chief Executive Officer of Neo, Neo and Hudson Resources entered into the August 2022 agreement through which Neo pursued Sarfartoq as a potential source of NdPr-rich feedstock for diversified rare earth supply chains. He will advise Greenland Mines on rare earth strategy, processing and product development, market positioning, potential offtake and strategic partnerships, government engagement and relationships across North American and European critical-minerals supply chains.

Thomas Abraham-James

Mr. Abraham-James, BSc (Hons), FAusIMM (CP Geo), FSEG and FGSL, is a geologist, entrepreneur and public-company executive with approximately 20 years of international mineral exploration, project-development and corporate experience. He holds a Bachelor of Science degree with First-Class Honours in Geology from the Australian National University. His honours research examined the evolution and mineralization of South Africa’s Bushveld Complex, one of the world’s most significant platinum-group-metal systems. He began his professional career as a mine geologist with Rio Tinto at the Argyle Diamond Mine before moving into international mineral exploration.

From 2008 to 2012, Mr. Abraham-James served as Exploration Manager of Platina Resources Limited, where he managed the company’s 2008, 2009 and 2010 Greenland field seasons and worked directly on Skaergaard. His first-hand knowledge of the Project’s geology, mineralized horizons, historical technical programs and Arctic field operations provides Greenland Mines with valuable continuity as the Company integrates legacy knowledge with its current S-K 1300 work, metallurgical testing and engineering studies.

Mr. Abraham-James subsequently co-founded Helium One Global Ltd, the first publicly listed company focused specifically on primary helium exploration; founded Greenland-focused Longland Resources Ltd, which was later acquired by Conico Ltd; and co-founded Pulsar Helium Inc., where he currently serves as Chief Executive Officer and a director. He has also contributed to the development of modern primary-helium exploration methodologies and co-authored technical publications, including The Principles of Helium Exploration.

Through these roles, Mr. Abraham-James has built experience across project generation, technical-program design, financing, public markets, processing and commercialization strategy, government engagement and the positioning of critical-resource projects within resilient Western supply chains. He will advise Greenland Mines on Skaergaard’s technical and development strategy, exploration and study design, Greenland field execution, corporate development, strategic partnerships and capital-markets positioning.

Bent Olsvig Jensen

Mr. Olsvig Jensen is a Greenland-based mining executive with approximately 30 years of leadership and operating experience in Greenland across education, the fishing industry, logistics, project management, mineral exploration and mine development. He holds a Bachelor of Education from Aalborg Seminarium and has completed postgraduate studies in educational administration, institutional development, information technology and economics, together with Danish military leadership training.

Mr. Olsvig Jensen has held senior executive roles associated with two of the relatively few Greenland mining projects to have progressed into operation since Greenland assumed responsibility for its mineral resources in 2010. From 2011 to 2016, he served as Chief Executive Officer of True North Gems Greenland during the development, permitting and construction phases of the Aappaluttoq ruby project. He subsequently served as Chief Executive Officer of Xploration Services Greenland, leading a Greenlandic service company that provided operational and turnkey support to mineral-exploration and development projects across the country.

From 2020 through August 2026, Mr. Olsvig Jensen served as Managing Director in Greenland for Lumina Sustainable Materials, leading the development and operation of the White Mountain, or Qaqortorsuaq, anorthosite mine in the Kangerlussuaq fjord region near Sarfartoq. His experience encompasses project financing, operational planning, Arctic logistics and infrastructure, regulatory compliance, workforce and contractor management, government relations, community engagement and the export of Greenlandic mineral products to international markets.

Mr. Olsvig Jensen has chaired the Mineral Resources Industry Committee of the Greenland Business Association since 2020 and, through that position, serves on the association’s board, representing the interests of Greenland’s exploration and mining sector. He also chairs Iserit A/S, the Nuuk municipality-owned property-management company. He founded NEMCo – Nuna Exploration & Mining Consultancy and, following his departure from Lumina, is focusing the consultancy on responsible mineral development and engagement among companies, investors, authorities, communities and other Greenlandic stakeholders.

Mr. Olsvig Jensen’s combination of mine-operating experience, corporate leadership and deep knowledge of Greenlandic society and Arctic operating conditions will be particularly valuable as Greenland Mines advances Sarfartoq into engineering, infrastructure, environmental and social assessment, permitting and feasibility-stage work. He will advise the Company on practical mine development and operations, logistics and infrastructure, permitting strategy, local participation and workforce development, and engagement with Greenlandic authorities, communities and businesses.

Advisory Capability for the Next Phase

The appointments follow a period of rapid project and corporate advancement. Greenland Mines completed the acquisition of Sarfartoq on September 1, 2026, after receiving approval from Naalakkersuisut, the Government of Greenland.

The Sarfartoq Project’s recently published Initial Assessment reported a high-case pre-tax NPV at an 8% real discount rate of approximately US$2.05 billion and a pre-tax IRR of 118.6%, including Indicated and Inferred Mineral Resources. At 2025 consumption levels, planned annual NdPr oxide production attributable to ST1 alone would represent approximately 34% of NdPr oxide refined outside China during each of the Project’s nine scheduled operating years.

Sarfartoq’s maiden 2026 S-K 1300 Mineral Resource Estimate, effective July 31, 2026, established the Project’s first Indicated Mineral Resource under an SEC-recognized standard. The preferred hybrid open-pit and underground configuration comprises 12.2 million tons in total, including 6.90 million tons Indicated at 1.60% total rare earth oxides (“TREO”) and 5.34 million tons Inferred at 0.96% TREO. Its strategic strength lies not only in grade but in the value composition of the basket: neodymium and praseodymium represent 83.9% of modeled in-concentrate basket value, with terbium and dysprosium contributing a further 8.5%. Neo Performance Materials retains previously announced offtake rights for up to 60% of future Sarfartoq ore or mineral concentrate production, providing a potential connection to Western-allied rare earth separation and magnet capacity.

Greenland Mines’ next phase at Sarfartoq is directed toward an application to Naalakkersuisut for an exploitation license. In parallel, the Company is planning a technical program for Sarfartoq covering resource upgrading, engineering, infrastructure assessment and scaled metallurgical and processing-flowsheet test work, with the objective of advancing to a Pre-Feasibility Study while continuing discussions regarding additional offtake and strategic partnerships. Two years of environmental baseline field studies have now been completed, providing a foundation for planned environmental and social impact assessment studies.

At Skaergaard, the Company’s 2026 S-K 1300 Mineral Resource Estimate, effective July 3, 2026, reported 153.6 million tons of Indicated Mineral Resources containing 7.57 million ounces of palladium, 3.19 million ounces of gold and 0.60 million ounces of platinum, equivalent to 15.00 million ounces on a palladium-equivalent basis. A further 177.5 million tons of Inferred Mineral Resources contain 7.75 million ounces of palladium, 4.28 million ounces of gold and 0.60 million ounces of platinum, equivalent to 17.49 million palladium-equivalent ounces. The estimate uses a net smelter return cut-off of US$84 per ton based on an underground mining scenario and covers only approximately one-quarter to one-third of the intrusion hosting the defined precious-metal horizons.

The extensive 2026 Skaergaard field campaign is now being concluded after generating the data and material required for the next stage of project evaluation. Operating from the ice-class M/V Argus as an offshore logistics platform, the multidisciplinary program included drilling and geotechnical work relevant to potential open-pit and underground scenarios; a seven-site bulk-sampling program that collected approximately 104.8 tons of mineralized and host material for large-scale and pilot-scale metallurgical test work; bathymetric, photogrammetric and ground-penetrating radar surveys; environmental baseline work; and on-site studies covering mine engineering, infrastructure, processing, tailings and waste-rock management.

The results of this program are intended to feed directly into resource evaluation, pilot-plant processing work, a maiden Initial Assessment, planned Pre-Feasibility Study work and the technical and environmental workstreams required to support a future exploitation-license application. No Initial Assessment or Pre-Feasibility Study has yet been completed for Skaergaard, no Mineral Reserve has been declared, and no production decision has been made.

Building the North Atlantic Corridor

The Strategic Advisory Board will also support Greenland Mines’ broader North Atlantic Critical Metals Corridor strategy, which is designed to connect responsibly developed Greenlandic resources with processing, infrastructure, industrial partners and end markets in allied jurisdictions.

For Sarfartoq, the previously announced relationship with Neo Performance Materials provides a potential route from an NdPr-rich Greenlandic resource to established European separation and magnet capacity. For Skaergaard, high-value, low-volume precious-metal products may offer comparatively flexible export options, while potential VTM-derived products would require a more energy- and infrastructure-intensive solution. Greenland Mines therefore holds a First Right of Refusal over the Helguvík industrial site in Iceland, a brownfield former silicon-metal facility approximately 400 kilometers by sea from Skaergaard, with deep-water port access, existing industrial infrastructure and access to Iceland’s renewable-power system.

Together, these potential routes form a strategic Greenland-to-allied-processing concept spanning rare earth magnet materials, precious metals and critical-mineral by-products.

The Corridor remains a development strategy: its processing configurations, logistics, power requirements, economics, partnerships and permitting remain subject to future technical, commercial, environmental and economic studies.

The Advisory Board is intended to help the Company test those assumptions, identify the right counterparties and sequence the work required to translate that strategy into executable project pathways.

About Greenland Mines Ltd

Greenland Mines Ltd is a Nasdaq-listed resource development and mining company focused on the development of the Skaergaard Project in southeast Greenland and the Sarfartoq neodymium-praseodymium rare earths project in southwest Greenland. The Company’s strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and select midstream processing opportunities, while advancing its assets and broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.

Technical Information

The scientific and technical information in this news release relating to Skaergaard is derived from the Company’s July 15 and September 11, 2026 news releases and the S-K 1300 Technical Report Summary referenced therein. The scientific and technical information relating to Sarfartoq is derived from the Company’s August 24, August 25 and September 2, 2026 news releases and the S-K 1300 Technical Report Summaries referenced therein. Readers should review those disclosures and the full Technical Report Summaries for the assumptions, qualifications and cautionary statements applicable to the Mineral Resource Estimates and Initial Assessment.

The Sarfartoq Initial Assessment is preliminary in nature and includes Inferred Mineral Resources that are considered too speculative geologically to have modifying factors applied to them that would enable them to be categorized as Mineral Reserves. There is no certainty that the results of the Initial Assessment will be realized, and no Mineral Reserves have been estimated for Sarfartoq. Mineral Resources are not Mineral Reserves and do not have demonstrated economic viability. Field-measured tonnage from the Skaergaard bulk-sampling program is preliminary and subject to confirmation during the next phase of test work. Potential Skaergaard by-products, processing routes and development configurations remain conceptual and are not supported by an economic study.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are often identified by words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “potential,” “could,” “may,” “will,” “should,” “estimate,” “objective” and similar expressions. These forward-looking statements include, but are not limited to, statements regarding: the intended role, activities and expected contributions of the Strategic Advisory Board and its members; the expected appointment of additional members; plans and timing for resource upgrading, metallurgical testing, engineering, environmental and social studies, Initial Assessments, Pre-Feasibility Studies and exploitation-license applications; potential production, processing, infrastructure, logistics, offtake and strategic partnerships; planned 2027 and 2028 work; the results and assumptions of the Sarfartoq Initial Assessment; potential future production and supply-chain significance; potential Skaergaard mining, processing and product configurations; the Helguvík industrial site and the North Atlantic Critical Metals Corridor; and the advancement and potential development of Skaergaard and Sarfartoq.

Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties. Many factors could cause actual results to differ materially, including exploration, resource-estimation, metallurgical, engineering, environmental, social, permitting, logistical, infrastructure, financing, commodity-price, market, counterparty and execution risks; the availability and level of participation of advisory board members; changes to planned programs and timelines; the Company’s ability to obtain required approvals and financing; and risks described in documents filed or to be filed with the U.S. Securities and Exchange Commission. No assurance can be given that studies, applications, partnerships, transactions, development decisions or production will occur on the timing contemplated or at all.

Readers should carefully consider these factors and the other risks and uncertainties described in the Company’s SEC filings. All information in this press release is provided as of its date, and the Company undertakes no obligation to update any forward-looking statement except as required by applicable law.

Investor Contact and Corporate Communications:

ir@greenlandmines.com
Website: www.greenlandmines.com

Corporate Communications:

IBN
Austin, Texas
IBN.Ai
512.354.7000 Office

Editor@IBN.Ai

LOUISVILLE, Ky., Sept. 14, 2026 (GLOBE NEWSWIRE) — Churchill Downs Incorporated (Nasdaq: CHDN, “CDI,” “the Company”) announced today that it is launching a proposed $500 million in aggregate principal amount of senior secured Term Loan B due 2033 (“2033 TLB”). 

CDI intends to use the net proceeds from the 2033 TLB (i) to repay outstanding Term Loan B loans, (ii) to partially redeem 5.50% Senior Notes due 2027 (the “2027 Notes”), (iii) to fund related transaction fees and expenses, and (iv) for working capital and other general corporate purposes.

There can be no assurances that the Company will be successful in its marketing efforts or that it will be able to obtain the 2033 TLB. The consummation of the 2033 TLB is subject to market and customary conditions. The 2033 TLB is subject to customary gaming regulatory conditions. This press release is not a notice of redemption for the 2027 Notes.

About Churchill Downs Incorporated

Churchill Downs Incorporated (“CDI”) (Nasdaq: CHDN) has created extraordinary entertainment experiences for over 150 years, beginning with the Company’s most iconic and enduring asset, Churchill Downs Racetrack, the home of the Kentucky Derby and premier races of the Thoroughbred Championship Series. Headquartered in Louisville, Kentucky, CDI has expanded through the acquisition, development, and operation of live and historical racing entertainment venues, the growth of the online wagering businesses, and the acquisition, development, and operation of regional casino gaming properties. https://www.churchilldownsincorporated.com/

This news release contains various “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are typically identified by the use of terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “predict,” “project,” “seek,” “should,” “will,” “scheduled,” and similar words or similar expressions (or negative versions of such words or expressions), although some forward-looking statements are expressed differently.

Although we believe that the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Important factors that could cause actual results to differ materially from expectations include the following: the occurrence of extraordinary events, such as terrorist attacks, public health threats, civil unrest, and inclement weather, including as a result of climate change; the effect of economic conditions on our consumers’ confidence and discretionary spending or our access to credit, including the impact of inflation; changes in, or new interpretations of, applicable tax laws or rulings that could result in additional tax liabilities; the impact of any pandemics, epidemics, or outbreaks of infectious diseases, and related economic matters on our results of operations, financial conditions, and prospects; lack of confidence in the integrity of our core businesses or any deterioration in our reputation; negative shifts in public opinion regarding gambling that could result in increased regulation of, or new restrictions on, the gaming industry; loss of key or highly skilled personnel, as well as general disruptions in the general labor market; the impact of significant competition, and the expectation that competition levels will increase; changes in consumer preferences, attendance, wagering, and sponsorships; risks associated with equity investments, strategic alliances and other third-party agreements; inability to respond to rapid technological changes in a timely manner; concentration and evolution of slot machine and historical racing machine manufacturing and other technology conditions that could impose additional costs; failure to enter into or maintain agreements with industry constituents, including horsemen and other racetracks; cybersecurity risk, including cybersecurity breaches, loss or misuse of our confidential information as a result of a breach including customers’ personal information, or IT system operational disruptions, could lead to government enforcement actions or other litigation; costs of compliance with increasingly complex laws and regulations regarding data privacy and protection of personal information; reliance on our technology services and catastrophic events, system failures, errors or defects disrupting our operations; inability to identify, complete, or fully realize the benefits of our proposed acquisitions, divestitures, development of new venues or the expansion of existing facilities on time, on budget, or as planned; difficulty in integrating recent or future acquisitions into our operations; cost overruns and other uncertainties associated with the development of new venues and the expansion of existing facilities; general risks related to real estate ownership and significant expenditures, including risks related to environmental liabilities; personal injury litigation related to injuries occurring at our racetracks; compliance with the Foreign Corrupt Practices Act or other similar laws and regulations, or applicable anti-money laundering regulations; payment-related risks, such as risk associated with fraudulent credit card or debit card use; work stoppages and labor problems; risks related to pending or future legal proceedings and other actions; highly regulated operations and changes in the regulatory environment could adversely affect our business; restrictions in our debt facilities limiting our flexibility to operate our business; failure to comply with the financial ratios and other covenants in our debt facilities and other indebtedness; increases to interest rates, disruption in the credit markets or changes to our credit ratings may adversely affect our business; increase in our insurance costs, or inability to obtain similar insurance coverage in the future, and any inability to recover under our insurance policies for damages sustained at our properties in the event of inclement weather and casualty events; whether the objective of a strategic alternative review process will be achieved; the terms, structure, benefits and costs of any strategic transaction; the timing of any strategic transaction and whether any strategic transaction will be consummated on the terms proposed or at all; the risk that the announcement or exploration of strategic alternatives could have an adverse effect on our ability to retain key personnel and maintain relationships with partners, suppliers, employees, shareholders and other business relationships; the risk of any unexpected costs or expenses resulting from the exploration of strategic alternatives; the risk of any litigation relating to the exploration of strategic alternatives or any strategic transaction; and other factors described under the heading “Risk Factors” in our most recent Annual Report on Form 10-K and in other filings we make with the Securities and Exchange Commission.

We do not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Investor Contact: Sam Ullrich
(502) 638-3906
Sam.Ullrich@kyderby.com

This press release was published by a CLEAR® Verified individual.

ISS Recognizes There is No Case for Change

Anavex Urges Stockholders to Follow ISS’ Recommendation and Vote “FOR” ALL Six Director Nominees on the WHITE Proxy Card Today

NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or “the Company”), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system diseases with high unmet medical needs, today announced that leading independent proxy advisory firm Institutional Shareholder Services (“ISS”) has recommended that Anavex stockholders vote on the WHITE proxy card “FOR” all six of the Company’s highly qualified director nominees standing for election at the 2026 Annual Meeting of Stockholders – Dr. Jiong Ma, Dr. Peter Donhauser, Dr. Axel Paeger, Mr. Gautam Patel, Dr. Adrian Senderowicz and Dr. Claus van der Velden.

In its report issued on September 11, 2026, ISS noted the substantive plan and strategy underway at Anavex and concluded that “[t]he dissident has not made a compelling case for change.”¹

In recommending “FOR” all six of the Anavex nominees on the WHITE proxy card, ISS also stated²:

• “[The EMA opinion] appears to have been a turning point, after which the board assumed a more active role that resulted in removal of the CEO.”
• “Since then, the board has also refreshed. Half of the board, when new nominees are included, is now composed of new members. It appears that the new board members bring experience in drug development, early-stage company development, and an understanding of the FDA approval process.”
• “The board also appointed an interim CEO and is moving towards hiring a permanent CEO, CFO, and CMO.”
  
  
• “Starting with the formation of the special committee and subsequent termination of the former CEO, the board appears to have acted decisively to remedy a situation that it admits was of its own making.”

The Executive Committee of Anavex’s Board issued the following statement:

ISS’ recommendation reaffirms that we have the right slate of Board nominees to continue driving long-term stockholder value and overseeing our new, focused strategy.

Our six nominees bring the biotechnology, clinical research, pharmaceutical development, regulatory and public company experience Anavex needs at this stage, and, if elected, half the Board will have been refreshed since the beginning of 2026, with every director as independent.

ISS agrees that “despite seeking a majority position, [PVG] has not presented a detailed go-forward plan.”³ We believe PVG’s slate, concentrated in investment management and equity research, would leave Anavex flailing and without focus, overseen by a Board deficient in the expertise that matters most.

We are grateful that ISS, after an independent review of both sides, is recommending “FOR” all six of our director nominees. We believe PVG’s attempt to seize control of the Board would disrupt Anavex’s progress at exactly the wrong moment for patients and stockholders alike.

Anavex strongly encourages all stockholders to follow ISS’ guidance and vote “FOR” ALL six of Anavex’s director nominees standing for election on their WHITE proxy card. For additional information on Anavex’s nominees and how to vote, visit www.VoteAnavex.com.

The Annual Meeting will be held on September 24, 2026, and stockholders of record as of the close of business on July 31, 2026 are entitled to vote.

Anavex stockholders with questions about or requiring assistance with voting shares, please call:

Innisfree M&A Incorporated
500 Fifth Avenue, 21^st Floor
New York, NY 10110
Stockholders may call toll-free at (877) 750-0831
Brokers, banks and other nominees may call collect at (212) 750-5833

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders. Further information is available at www.anavex.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements regarding the Company’s plans, strategies and expectations regarding the 2026 Annual Meeting, director nominations, the proxy solicitation, the Company’s go-forward strategy, clinical development programs, business prospects, and potential actions of the Board and the Executive Committee, are forward-looking statements. These statements can be identified by the use of forward-looking terminology, including the words “believes,” “anticipates,” “plans,” “estimates,” “expects,” “intends,” “may,” “will,” “would,” “could” and similar expressions, or the negative thereof. Many factors may cause actual results to differ materially from those projected in any of such forward-looking statements, including the risks and uncertainties set forth in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2025, filed with the Securities and Exchange Commission (“SEC”) on November 25, 2025, the Company’s Quarterly Report on Form 10-Q for the quarterly period ended December 31, 2025, filed with the SEC on February 9, 2026, the Company’s Form 10-K/A for the fiscal year ended September 30, 2025, filed with the SEC on August 28, 2026, the Company’s Form 10-Q/A for the quarterly period ended December 31, 2025, filed with the SEC on August 28, 2026, the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026, filed with the SEC on August 28, 2026, the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, filed with the SEC on August 28, 2026, and subsequent filings and furnishings with the SEC, which should be considered together with any forward-looking statement. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof except as required by law.

Important Additional Information and Where to Find It
The Company has filed a definitive proxy statement on Schedule 14A, an accompanying WHITE proxy card, and other relevant documents with the SEC in connection with the solicitation of proxies from the Company’s stockholders for the 2026 Annual Meeting. THE COMPANY’S STOCKHOLDERS ARE STRONGLY ENCOURAGED TO READ THE COMPANY’S DEFINITIVE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO), THE ACCOMPANYING WHITE PROXY CARD AND OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN IMPORTANT INFORMATION. Stockholders are able to obtain the definitive proxy statement, any amendments or supplements to the proxy statement and other documents that the Company files with the SEC at no charge at the SEC’s website at www.sec.gov. Copies are also available at no charge at the Company’s website at www.anavex.com.

Certain Information Regarding Participants
The Company, its directors and certain of its executive officers may be deemed to be “participants” (as defined in Schedule 14A under the Securities Exchange Act of 1934, as amended) in the solicitation of proxies from the Company’s stockholders in connection with the matters to be considered at the 2026 Annual Meeting. Information regarding the names of the Company’s directors and executive officers and certain other individuals and their direct or indirect interests in the Company, by security holdings or otherwise, is set forth in the sections entitled “Compensation of Directors,” “Executive Compensation,” and “Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters” of the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2025 (available here), and any subsequent filings on Forms 3, 4 and 5 filed with the SEC. Additional information regarding the identity of potential participants, and their direct or indirect interests, by security holdings or otherwise, is set forth in the Company’s definitive proxy statement for the 2026 Annual Meeting which has been filed with the SEC. These documents are available free of charge at the SEC’s website at www.sec.gov.

Investor Relations:
SCR Partners, LLC
Alex Arzeno
Tel: 203-550-3972
Email: alex@scr-ir.com

Tripp Sullivan
Tel: 615-942-7077
Email: tsullivan@scr-ir.com

For Media:
Collected Strategies
Nick Lamplough / Dylan O’Keefe
AVXL-CS@collectedstrategies.com

_________________________________
¹ Permission to use quotations neither sought nor obtained.
² Permission to use quotations neither sought nor obtained.
³ Permission to use quotations neither sought nor obtained.

Under the terms of the Amendment, all disputed issues are resolved

SAN DIEGO and NERVIANO, Italy, Sept. 14, 2026 (GLOBE NEWSWIRE) — Cardiff Oncology, Inc. (NASDAQ: CRDF) (“Cardiff”) and Nerviano Medical Sciences S.r.l. (“NMS”) today announced that they have reached a settlement and amended their 2017 Exclusive License Agreement, resolving all outstanding disputes between the two companies related to the global rights for onvansertib, Cardiff’s lead PLK1 inhibitor drug candidate, and establishing an expanded collaborative framework to support onvansertib’s continued clinical development.

Cardiff and NMS have agreed to a full and mutual release of all claims asserted in the litigation pending in the U.S. District Court for the Southern District of California. Cardiff and NMS plan to jointly request dismissal of all claims with prejudice.

“This Amendment strengthens our long-term rights to onvansertib as a promising treatment for cancer, beginning with first-line RAS-mutated metastatic colorectal cancer,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “We are pleased to be entering into this agreement with NMS, which reflects our shared commitment to bringing onvansertib to patients with high unmet need.”

“We look forward to working with Cardiff to advance onvansertib into a global Phase 3 study in first-line RAS-mutated metastatic colorectal cancer and to bring this therapy to patients,” said Hugues Dolgos, PharmD, Chief Executive Officer of NMS Group S.r.l.

The Parties clarified and expanded on the royalty structure in the License Agreement. The agreement also includes development objectives related to Cardiff’s upcoming Phase 3 program, as well as rights for NMS to appoint a Board observer and join Cardiff’s Scientific Advisory Board.

About Onvansertib
Onvansertib is a highly specific, oral PLK1 inhibitor advancing toward a registrational trial in first-line RAS-mutated mCRC. In a randomized Phase 2 trial, onvansertib in combination with FOLFIRI/bevacizumab (first-line standard-of-care) demonstrated dose-dependent improvements in overall response rate and progression-free survival compared to standard-of-care alone, building on findings from a prior Phase 2 trial in second-line RAS-mutated mCRC. Based on these results, the Company has selected the 30 mg dose of onvansertib in combination with FOLFIRI/bevacizumab for advancement into a registrational trial in first-line patients with RAS-mutated mCRC.

About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company advancing innovative cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Cardiff’s lead asset, onvansertib, is a highly specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated mCRC, addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single-agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, we aim to overcome treatment resistance and deliver improved clinical outcomes for patients.

About NMS
NMS is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative oncology therapies. Building on a long-standing heritage in cancer biology and drug discovery, NMS combines a focused clinical-stage small-molecule portfolio with a differentiated ADC platform and an active discovery engine generating first-in-class oncology programs. NMS has operations in Italy, the United States, China and Hong Kong.

Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend” or other similar terms or expressions that concern Cardiff Oncology’s expectations, strategy, plans or intentions. These forward-looking statements are based on Cardiff Oncology’s current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidate; results of preclinical studies or clinical trials for our product candidate could be unfavorable or delayed; our need for additional financing; risks related to business interruptions, including the outbreak of COVID-19 coronavirus and cyber-attacks on our information technology infrastructure, which could seriously harm our financial condition and increase our costs and expenses; uncertainties of government or third-party payer reimbursement; dependence on key personnel; limited experience in marketing and sales; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. There are no guarantees that our product candidate will be utilized or prove to be commercially successful. Additionally, there are no guarantees that future clinical trials will be completed or successful or that our product candidate will receive regulatory approval for any indication or prove to be commercially successful. Investors should read the risk factors set forth in Cardiff Oncology’s Form 10-K for the year ended December 31, 2025, and other periodic reports filed with the Securities and Exchange Commission. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and Cardiff Oncology does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances.

For more information regarding Cardiff, please visit https://www.cardiffoncology.com.

Cardiff Investor Contact: 
Candice Masse 
Astr Partners 
candice.masse@astrpartners.com 

Cardiff Media Contact:
Amy Bonanno
Lyra Strategic Advisory
abonanno@lyraadvisory.com

For more information regarding NMS, please visit https://www.nervianoms.com/

NMS Media Contact: 
mediarelations@nervianoms.com

This transaction is in addition to the previously announced pending sale of Altruis Benefit Consulting

LAKEWOOD, NJ, Sept. 14, 2026 (GLOBE NEWSWIRE) — Reliance Global Group, Inc. (Nasdaq: EZRA) (“Reliance,” “EZRA” or the “Company”), an InsurTech company leveraging artificial intelligence, cloud computing and advanced technologies to transform the insurance agency/brokerage industry, today announced that it has completed the sale of its Southwestern Montana Insurance Center subsidiary, a Montana-based full-service insurance agency, for $2.625 million in cash at closing, plus an uncapped earnout, if any, based on the agency’s EBITDA performance for the twelve months ending August 31, 2027. No shares were issued in connection with the transaction. The Southwestern Montana Insurance Center sale is in addition to the previously announced expected sale of the Michigan-based Altruis Benefit Consulting agency.

The completed transaction represents the continued execution of the portfolio monetization strategy of non-core agencies that Reliance launched in 2025. The Company is selectively monetizing mature insurance agency assets to strengthen its balance sheet and redeploy capital into its proprietary AI platform, RELI Exchange, other high-growth InsurTech initiatives, and accelerate the repayment of the company’s term debt.

Key Terms and Expected Impact

• Cash at closing plus uncapped earnout; zero dilution. The Company received $2.625 million in cash at closing, based on a multiple of 8.75 times pro forma EBITDA of $300,000. In addition, the transaction provides for an uncapped earnout, if any, equal to 8.75 times the amount by which the agency’s EBITDA exceeds $300,000 for the twelve months ending August 31, 2027, payable, if earned, following the first anniversary of the closing. No shares were issued in connection with the transaction.
• Transaction completed. The sale of Southwestern Montana Insurance Center closed on September 11, 2026, effective as of September 1, 2026, marking the successful completion of another transaction under the Company’s portfolio monetization strategy.
• Continued execution of the strategy. The completed transaction represents further execution of a non-core agency divestiture under the Company’s portfolio monetization strategy and demonstrates the Company’s continued discipline in unlocking the value of Reliance’s non-core assets while increasing investment in higher-growth technology initiatives.
• Enhanced financial flexibility. The completed transaction provides the Company with additional capital and financial flexibility to support operations, growth and strategic investment, including continued investment in its proprietary AI platform, RELI Exchange and other technology initiatives.

Strategic Rationale

In 2025, Reliance launched a portfolio monetization strategy to unlock the value of non-core insurance agency assets while accelerating its evolution into a technology-driven InsurTech company. By selectively monetizing established insurance operations, the Company expects to strengthen its balance sheet, improve financial flexibility and redeploy capital into its proprietary AI platform, RELI Exchange and other strategic growth initiatives that management believes offer greater long-term growth opportunities.

The completed Southwestern Montana transaction represents another milestone in executing the strategy. The transaction is expected to strengthen the Company’s financial position and increase the capital available to accelerate development of the Company’s proprietary AI platform, expand the RELI Exchange network and pursue additional strategic growth opportunities.

“The completed sale of Southwestern Montana Insurance Center reflects the continued execution of our portfolio monetization strategy, a disciplined capital allocation approach designed to unlock the value of our mature insurance agency portfolio and redeploy that capital into higher-growth opportunities,” said Ezra Beyman, Chairman and Chief Executive Officer of Reliance Global Group. “This transaction was driven by strategy and reflects our commitment to building a stronger, more focused technology-driven company while maximizing long-term shareholder value.”

“This closing builds on the momentum of our recent tech developments and represents another step in repositioning Reliance for its next phase of growth,” Mr. Beyman continued. “We believe this transaction provides us with greater financial flexibility and increased capacity to invest in our AI platform, RELI Exchange and other strategic growth initiatives. We believe this disciplined approach positions Reliance to create meaningful long-term value for our shareholders.”

About Reliance Global Group, Inc.

Reliance Global Group, Inc. (Nasdaq: EZRA) is an InsurTech company leveraging artificial intelligence, cloud computing and advanced technologies to transform the insurance agency/brokerage industry. Through its growing portfolio of proprietary AI solutions and insurance operations, the Company is focused on enhancing operational efficiency, improving customer experiences and creating long-term shareholder value. Further information about the Company can be found at https://www.relianceglobalgroup.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements other than statements of historical fact and may be identified by the use of words or expressions such as “may,” “should,” “could,” “would,” “will,” “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “continue,” “target,” “project,” “potential,” or similar expressions, or by discussions of strategy, plans or intentions. Forward-looking statements in this press release include, without limitation, statements regarding: the amount, timing and payment of the earnout consideration, if any; the anticipated benefits of the completed sale of Southwestern Montana Insurance Center; the previously announced proposed sale of Altruis Benefit Consulting, including the negotiation and execution of definitive agreements and the timing of any closing; the Company’s intended use of proceeds and the anticipated effects of the transaction on the Company’s cash position, capital structure and financial flexibility; the Company’s portfolio monetization strategy, including the monetization of mature insurance distribution assets and the redeployment of capital; and the continued development, deployment and potential commercialization of the Company’s proprietary artificial intelligence platform and its RELI Exchange InsurTech platform.

These statements are based on management’s current expectations and assumptions and are subject to risks, uncertainties and other factors, many of which are beyond the Company’s control. Should one or more of these risks or uncertainties materialize, or should any underlying assumptions prove incorrect, actual results may differ materially from those expressed or implied by these forward-looking statements.

Such risks and uncertainties include, without limitation: the risk that the earnout consideration is not earned or paid, in whole or in part, including because the EBITDA of the divested agency, which will be operated by the buyer following the closing, does not exceed the applicable threshold; the subordination of the Company’s right to receive the earnout consideration; the loss of the revenue and operating cash flow historically contributed by Southwestern Montana Insurance Center and the resulting impact on the Company’s consolidated results of operations; with respect to the proposed Altruis transaction, the risk that definitive agreements are not negotiated or executed, that closing conditions are not satisfied or waived, or that the transaction is delayed or terminated; the risk that the Company is unable to redeploy capital into initiatives that generate the anticipated returns; the Company’s ability to maintain compliance with the continued listing standards of The Nasdaq Capital Market; the Company’s ability to access additional capital on acceptable terms, or at all; the development, deployment, market acceptance and potential commercialization of the Company’s proprietary artificial intelligence technologies; competition, regulatory developments and other risks affecting the insurance brokerage and InsurTech industries; and general business, economic, market and geopolitical conditions. Additional information regarding these and other factors that may cause actual results to differ materially is included under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as amended, and in the Company’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission, copies of which are available free of charge at www.sec.gov.

Readers are cautioned not to place undue reliance on forward-looking statements. The forward-looking statements in this press release speak only as of the date of this press release. Except as required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Investor Relations Contact:
Crescendo Communications, LLC
Tel: +1 (212) 671-1020
Email: EZRA@crescendo-ir.com